Sasaki K, Kantarjian H, Jabbour E, Ravandi F, Takahashi K, Konopleva M, Borthakur G, Garcia-Manero G, Wierda W, Daver N, Jain P, Satta T, Pierce S, Rios MB, Cortes JE. Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia – a propensity score analysis. Haematologica [Internet]. 2016Jul.31 [cited 2026Nov.13];101(8):e324-e327. Available from: https://haematologica.org/article/view/7804